No Data
No Data
Interpretation of ESG Annual Report|Yisheng Biotechnology (01061) Releases 2023 ESG Report Greenhouse Gas Density Decreased by 33.3% YoY
Zhitong Finance App News. Recently, Yisheng Biotechnology (01061) released the “2023 Environmental, Social and Governance Report”, which sets out the Group's strategies and practices in the three areas of environmental protection, social responsibility and operational governance for the year ended December 31, 2023, covering the business operated by the Group. According to reports, Yisheng Biotechnology is mainly engaged in manufacturing, sales, marketing and distribution of pharmaceuticals, and its main operating area is China. According to the ESG report, the board of directors of Yisheng Biotech bears full responsibility for the company's ESG strategy and ESG report, and is responsible for evaluating and determining ESG-related risks and
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
ESSEX BIO-TECH: ANNUAL REPORT 2023
No Data